Clopidogrel resistance is associated with thromboembolic complications in patients undergoing neurovascular stenting

American Journal of Neuroradiology

Volumn 34, Issue 4, 2013, Pages 716-720

  Fifi, J T ^a   Brockington, C ^b   Narang, J ^b   Leesch, W ^a   Ewing, S L ^b   Bennet, H ^b   Berenstein, A ^a   Chong, J ^b  

^a Center for Endovascular Surgery   (United States)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; CAROTID ARTERY INJURY; CAROTID ARTERY STENT; CAROTID ARTERY STENTING; CAROTID ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; THERAPY RESISTANCE; THROMBOEMBOLISM; TREATMENT OUTCOME;

AGED; ASPIRIN; BLOOD PLATELETS; CEREBRAL ARTERIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; ENDOVASCULAR PROCEDURES; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RETROSPECTIVE STUDIES; STENTS; THROMBOEMBOLISM; TICLOPIDINE;

EID: 84876725215     PISSN: 01956108     EISSN: 1936959X     Source Type: Journal    
DOI: 10.3174/ajnr.A3405     Document Type: Article

References (29)

1. Chimowitz MI, Lynn MJ, Derdeyn CP, et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med 2011;365:993-1003
2. Oxley TJ, Mitchell PJ, Yan B. Antiplatelet resistance and thromboembolic complications in neurointerventional procedures. Front Neurol 2011;2:83
3. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting: Stent anticoagulation restenosis study investigators. N Engl J Med 1998;339:1665-71 (Pubitemid 28550691)
4. Fiorella D. Anti-thrombotic medications for the neurointerventionist: Aspirin and clopidogrel. J Neurointerv Surg 2010;2:44-49
5. Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107:2908-13 (Pubitemid 36736631)
6. Jaremo P, Lindahl TL, Fransson SG, et al. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 2002;252:233-38
7. Price MJ, Coleman JL, Steinhubl SR, et al. Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers. Am J Cardiol 2006;98:681-84 (Pubitemid 44233472)
8. Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;56:919-33
9. Pinto Slottow TL, Bonello L, Gavini R, et al. Prevalence of aspirin and clopidogrel resistance among patients with and without drugeluting stent thrombosis. Am J Cardiol 2009;104:525-30
10. Lee Dh AA, Morsi H, Shaltoni H, et al. Dual antiplatelet therapy monitoring for neurointerventional procedures using a point-ofcare platelet function test: A single-center experience. AJNR Am J Neuroradiol 2008;29:1389-94
11. Muller-Schunk SL, Peters N, Spannagl M, et al. Monitoring of clopidogrel-related platelet inhibition: Correlation of nonresponse with clinical outcome in supra-aortic stenting. AJNR Am J Neuroradiol 2008;29:786-91 (Pubitemid 351571565)
12. Prabhakaran S, Wells KR, Lee VH, et al. Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting. AJNR Am J Neuroradiol 2008;29:281-85 (Pubitemid 351287881)
13. Drazin D, Choulakian A, Nuno M, et al. Body weight: A risk factor for subtherapeutic antithrombotic therapy in neurovascular stenting. J Neurointerv Surg 2011;3:177-81
14. Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: A multicenter randomized prospective study. J Am Coll Cardiol 2008;51:1404-11 (Pubitemid 351447314)
15. Ari H, Ozkan H, Karacinar A, et al. The effect of high-dose clopidogrel treatment in patients with clopidogrel resistance (the EFFICIENT trial). Int J Cardiol 2012;157:374-80
16. Aradi D, Rideg O, Vorobcsuk A, et al. Justification of 150 mg clopidogrel in patients with high on-clopidogrel platelet reactivity. Eur J Clin Invest 2012;42:384-92
17. van Werkum JW, Hackeng CM, Smit JJ, et al. Monitoring antiplatelet therapy with point-of-care platelet function assays: A review of the evidence. Future Cardiol 2007;49;1505-16
18. Maruyama TH, Dembo T, Nagoya H, et al. Clopidogrel resistance and the effect of combination cilostazol in patients with ischemic stroke or carotid artery stenting using the VerifyNow P2Y12 assay. Int Med 2011;50:695-98
19. Shim CY, Yoon SJ, Park S, et al. The clopidogrel resistance can be attenuated with triple antiplatelet therapy in patients undergoing drug-eluting stents implantation. Int J Cardiol 2009;134:351-55
20. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: Clinical implications, management, and future perspectives. J Am Coll Cardiol 2007;49: 1505-16 (Pubitemid 46517957)
21. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171-75
22. Lev EI, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: The role of dual drug resistance. J Am Coll Cardiol 2006;47:27-33 (Pubitemid 43005160)
23. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009;302:849-57
24. Hochholzer W, Trenk D, Fromm MF, et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol 2010;55: 2427-34
25. Mega JL, Hochholzer W, Frelinger AL, et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA 2011;306: 2221-28
26. Breet NJ, van Werkum JW, Bouman HJ, et al. High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention. Heart 2011;97;983-90
27. Price MJ, Berger PB, Teirstein PS, et al for the GRAVITAS Investigators. Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: The GRAVITAS randomized trial. JAMA 2011;305:1097-105
28. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial. Lancet 2004;364: 331-37
29. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15 (Pubitemid 350106708)